Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DR REDDYS LABORATORIES LTD Capital/Financing Update 2025

Mar 22, 2025

30528_rns_2025-03-22_b3a10f75-bec3-48a9-84ed-8c4596960a7d.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India

==> picture [147 x 33] intentionally omitted <==

CIN: L85195TG1984PLC004507

Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: [email protected] Web: www.drreddys.com

March 22, 2025

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Completion of sale of step down wholly owned subsidiary of the Company.

Further to our intimation dated January 7, 2025, we wish to inform you that Dr. Reddy’s Laboratories Inc., USA, a wholly owned subsidiary of the Company, has successfully completed the sale of all issued and outstanding membership interests in its wholly owned subsidiary viz; Dr. Reddy’s Laboratories Louisiana LLC, including the manufacturing facility located in Shreveport, Louisiana, USA, on March 21, 2025.

Consequently, Dr. Reddy’s Laboratories Louisiana LLC has ceased to be a wholly owned subsidiary of Dr. Reddy’s Laboratories Inc. and a step-down wholly owned subsidiary of Dr. Reddy’s Laboratories Limited effective from March 21, 2025.

This is for your information and records.

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

KUMAR Digitally signed by KUMAR RANDHIR RANDHIR SINGH Date: 2025.03.22 SINGH 12:19:33 +05'30'

K Randhir Singh

Company Secretary, Compliance Officer, and Head-CSR